二、对公司的影响及风险提示 上述医疗器械注册证的变更是在原有注册证的基础上根据实际情况及相关 标准进行的相应变更。一次性使用无菌注射器（带针）、一次性使用无菌配药注 射器（带针）领域相关产品的实际销售情况取决于未来市场的推广效果，产品销 售及利润贡献具有不确定性，目前尚无法预测上述产品对公司未来业绩的影响， 敬请相关投资者给予关注并注意投资风险。 证券代码：300981 证券简称：中红医疗 公告编号：2025-059 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司完成医疗器械 变更注册的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得国家药品监督管理局及江西省药品监督管理局颁 发的《医疗器械变更注册（备案）文件》。具体变更情况如下： | 产品名称 | 注册证编号 | 注册分类 | 变更内容 | 备注 | | --- | --- | --- | --- | --- | | 一次性使用无 菌注射器 带针 | 国械注准 20153142006 | ...

Group 1: National Standard Release - The release of the mandatory national standard GB24788-2025 for medical gloves marks a significant milestone in the standardization process of the industry, set to be implemented on June 1, 2028 [1][2] - The new standard integrates and upgrades existing technical requirements, establishing a four-layer safety system covering "allergy prevention, infection control, dust control, and residue limits" [1][2] - Four core safety indicators are defined: limits on water-extracted protein to reduce allergy risks, enhanced microbial indicators to block infection transmission, limits on surface residual powder to improve safety, and strict limits on ethylene oxide residues to meet international health standards [1] Group 2: Company Overview - Zhonghong Medical, recognized as a national high-tech enterprise and a "little giant" in specialized innovation, exemplifies technical accumulation and innovation in the medical glove sector [3] - The company has been included in the list of "world-class specialized and innovative demonstration enterprises" by the State-owned Assets Supervision and Administration Commission, and is recognized as one of the "Top 50 Medical Device Companies in China" and "Top 500 Chinese Brands" [3] Group 3: Research and Development - Zhonghong Medical has established a collaborative research platform with universities, focusing on new material development and process optimization to break international monopolies in medical glove technology [4] - The company has accumulated 225 patents, with over 70 held by its subsidiary, Guilin Hengbao, including high-end products like polyisoprene (PI) gloves and antiviral gloves, setting benchmarks in the international market [4] Group 4: Internationalization and Quality Certification - Zhonghong Medical's products have received multiple international certifications, including FDA, CE, and ISO14001, ensuring compliance with the latest EU standards [5] - The company’s gloves are exported to over 80 countries and regions, with a 15.45% year-on-year revenue growth in Q1 2025, demonstrating strong market competitiveness [5] Group 5: Product Matrix - Zhonghong Medical has developed a comprehensive product matrix covering surgical gloves, examination gloves, and disposable protective gloves, catering to diverse medical, industrial, and consumer needs [6] Group 6: Future Outlook - The release of the national standard not only showcases Zhonghong Medical's technical strength but also reflects its commitment to social responsibility [11] - The company aims to continue driving innovation and participate in the construction of global standard systems, ensuring its products meet international requirements [11] - Zhonghong Medical is focused on promoting the medical glove industry towards green, intelligent, and high-end development through a collaborative model of "technology + standards + industry" [11]

Investment Rating - The report maintains an "Overweight" rating for the industry, indicating a projected investment return exceeding the market benchmark index by 5% to 15% over the next 6-12 months [5]. Core Insights - The report highlights a potential price turning point in the third quarter, driven by tariff increases on imports from Malaysia and China, which may lead to a recovery in the prices of disposable medical-grade nitrile gloves [1][2]. - The market structure is becoming increasingly stratified, with smaller manufacturers gradually exiting the industry due to competitive pressures and price declines, while leading domestic companies are expanding their production capacity [3]. - Domestic leaders like Yingke Medical are expected to release overseas production capacity by the end of the year, which is anticipated to enhance their market position and profitability [3][4]. Summary by Sections Industry Overview - The report discusses the impact of U.S. tariffs on disposable nitrile gloves, with a significant increase to 50% on certain Chinese products set to take effect in January 2025, potentially leading to price increases in the domestic market [2][3]. Market Dynamics - The report notes that the production capacity of disposable medical-grade nitrile gloves in China has been rapidly expanding, with Yingke Medical's annual capacity reaching 87 billion pieces by the end of 2024 [3]. - The competitive landscape is characterized by intense competition in non-U.S. markets, leading to price pressures and the exit of some smaller players from the market [3]. Future Outlook - The report suggests that as domestic leaders release overseas production capacity and with natural growth in end-user demand, the prices of disposable gloves are expected to return to reasonable levels, allowing domestic companies to capture a larger share of the global market [4]. - The report emphasizes the importance of cost control, supply chain integration, and R&D capabilities for domestic companies to enhance their competitive edge [4].

证券代码：300981 证券简称：中红医疗 公告编号：2025-058 中红普林医疗用品股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 中红普林医疗用品股份有限公司（以下简称"公司"）分别于 2024 年 12 月 9 日、2024 年 12 月 25 日召开第四届董事会第四次会议及第四届监事会第四次会 议、2024 年第三次临时股东大会，审议通过了《关于公司及子公司 2025 年度向 银行申请综合授信额度暨公司为子公司申请综合授信额度提供担保的议案》，同 意公司为控股子公司 2025 年度向金融机构申请的授信额度提供担保，其中，为 资产负债率 70%（含）以上的控股子公司提供担保额度为不超过 15 亿元，为资 产负债率低于 70%的控股子公司提供担保额度为不超过 10 亿元，担保额度总计 不超过 25 亿元。具体内容详见《关于公司及子公司 2025 年度向银行申请综合授 信额度暨公司为子公司申请综合授信额度提供担保的公告》（公告编号：2024- 083）。 二、担保进展情况 近日，为满足公司控股 ...

Core Viewpoint - Recently, Zhonghong Medical (300981.SZ) has gained attention in the capital market due to its subsidiary obtaining three medical device registration certificates and its plan to acquire a Southeast Asian glove manufacturer for 6.97 million RMB [1][3]. Group 1: Medical Device Registration - On July 8, Zhonghong Medical announced that its subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd., obtained two medical device registration certificates from the Jiangxi Provincial Drug Administration and one from the National Medical Products Administration [1]. - The registration certificates are for the continuation of existing products, with effective periods extended from original expiration dates in 2025 and 2026 to new dates in 2030 and 2031 [2]. - The extension of these certificates ensures the continued sales of products in the fields of disposable sterile care packages, disposable sterile syringes (with needles), and medical dressings, enhancing the company's competitive edge and market expansion capabilities [2]. Group 2: Acquisition of SEA3 Company - Zhonghong Medical plans to acquire 75% of the Southeast Asian SEA3 company for a total cash consideration of 6.97 million RMB, with Zhonghong Hong Kong acquiring 52.5% and Hengbao International acquiring 22.5% [3][5]. - Following the acquisition, Zhonghong Hong Kong and Hengbao International will inject additional capital into SEA3, totaling approximately 7.57 million RMB [5]. - SEA3 specializes in the production and sale of medical-grade gloves and holds various international certifications, including EU ISO13485, CE, and US FDA 510(k) [6]. Group 3: Financial Performance - As of March 31, 2025, SEA3 reported total assets of 136 million RMB and a net asset deficit of 492,400 RMB, with revenues of 6.56 million RMB and a net loss of 372,210 RMB for the first quarter of 2025 [6]. - Zhonghong Medical's performance in Q1 2025 showed revenues of 629 million RMB, a year-on-year increase of 15.45%, and a net profit of 18.92 million RMB, reflecting a significant year-on-year growth of 1369.95% [7].

Group 1 - The core viewpoint of the news is that Zhonghong Medical's subsidiary, Guilin Hengbao Health Protection Co., successfully won the bid for the "Ningbo University Affiliated Women's and Children's Hospital 2025 Annual Free Contraceptive Procurement Project," highlighting the company's strength in the medical device sector and solidifying its market leadership [1][2] - The project aims to provide free contraceptive devices to the citizens of Ningbo, ensuring reproductive health needs are met, and attracted participation from many well-known companies in the industry [1] - Zhonghong Medical's winning product, the condom made from polyisoprene (PI), stands out due to its material properties, which offer advantages over traditional latex condoms, such as better elasticity and reduced risk of allergic reactions [1][2] Group 2 - The "Beili Le" polyisoprene condom developed by Hengbao Health is described as super soft and skin-like, showcasing the company's expertise and product advantages in the condom market [2] - Zhonghong Medical is committed to the research, production, and sales of medical products, equipped with advanced production facilities and a strict quality control system to meet high-quality standards [2] - The company plans to increase R&D investment and enhance product competitiveness and service quality through technological innovation and quality control, while ensuring efficient and high-quality supply of free contraceptive devices for the Ningbo project [2]

证券代码：300981 证券简称：中红医疗 公告编号：2025-057 中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得 2 项江西省药品监督管理局颁发的《中华人民共和 国医疗器械注册证》和 1 项国家药品监督管理局颁发的《中华人民共和国医疗器 械注册证》，上述注册证为原有产品的延续注册，有效期限分别由原 2025 年 8 月 23 日到期变更为 2030 年 8 月 23 日到期，原 2025 年 10 月 19 日到期变更为 2030 年 10 月 19 日到期，原 2026 年 1 月 24 日到期变更为 2031 年 1 月 24 日到 期。上述注册证具体情况如下： 二、对公司的影响及风险提示 注册人名称 产品名称 注册证编号 注册分类 注册证有效期 适用范围 江西科伦医 疗器械制造 有限公司 一次性使用无 菌护理包 赣械注准 20202140547 Ⅱ类 2025 年 8 月 24 日至 2030 年 8 月 23 日 适用于医疗单位 对患者采血和输 液时的护理、消 毒、穿刺点保护， 防止感染。 一次性使用无 菌注射器 带 ...

Core Viewpoint - The acquisition of 75% stake in SEA3 by Zhonghong Medical at a low price of 6.97 yuan is a strategic move to navigate the challenges posed by the changing international trade environment, particularly the high tariffs imposed by the US on Chinese medical gloves [1][2]. Group 1: Acquisition Details - Zhonghong Medical's subsidiary Zhonghong Hong Kong plans to acquire SEA3, which has total assets of 141 million yuan [1]. - The acquisition involves a total capital increase of 75.68 million yuan, with Zhonghong Hong Kong and Hengbao International contributing 52.98 million yuan and 22.70 million yuan respectively [2]. Group 2: Market Context - The medical glove industry is significantly impacted by US tariffs, with rates as high as 80% on medical-grade nitrile gloves and 55% on industrial-grade nitrile gloves, severely affecting profit margins for domestic manufacturers [1]. - The acquisition is part of a broader trend where domestic companies are seeking to establish overseas production bases or pursue mergers and acquisitions to mitigate the impact of tariffs [1]. Group 3: Future Implications - The successful integration of SEA3 could enhance Zhonghong Medical's competitiveness in overseas markets and potentially reshape its profit curve in the long term [2]. - The company faces challenges in managing cultural and language differences post-acquisition, which may affect the realization of synergies [2].

Group 1 - The Ministry of Finance and the Ministry of Commerce of China announced measures to restrict government procurement of medical devices imported from the EU, effective from July 6, 2025, requiring a procurement budget of over 45 million RMB to exclude EU companies [2] - Non-EU companies can only have a maximum of 50% of their medical devices sourced from the EU in their contracts [2] Group 2 - The Ministry of Housing and Urban-Rural Development emphasized the importance of stabilizing the real estate market and called for tailored policies to promote healthy development [3] - The ministry's research team conducted discussions with local governments and industry experts to analyze the real estate market's performance in the first half of the year [3] Group 3 - Former President Trump announced new tariffs ranging from 10% to 70%, which could increase inflation risks for the U.S. economy [4] - The proposed tariffs are higher than previously announced "reciprocal tariffs" and could further impact the U.S. stock market [4] Group 4 - The company Renrenle officially delisted from the Shenzhen Stock Exchange after four consecutive years of losses, marking the end of its operations as a major supermarket chain [9] Group 5 - Zhonghong Medical announced a cash acquisition of 75% equity in SEA3 company for only 6.97 RMB, raising questions among investors about the accuracy of the reported amount [10][11] Group 6 - The company Romasi announced a six-month suspension of operations due to a recall crisis, with plans to pay employees 80% of the local minimum wage during this period [12] - Employees expressed concerns about the adequacy of the compensation in relation to living costs [12] Group 7 - NIO's founder Li Bin stated that the company's cumulative R&D investment has reached 60 billion RMB, emphasizing the transparency of its financial reports [14][15] Group 8 - China Shipbuilding Industry Corporation received approval for a major asset restructuring, merging with China Shipbuilding Heavy Industry Company, marking a significant step in consolidating its core listed platforms [16]

Core Viewpoint - The acquisition of 75% equity in SEA3 by Zhonghong Medical for a mere 6.97 yuan is perceived as a "bargain" deal, but it reflects the company's ongoing financial struggles and the risks associated with the acquisition [1][4]. Group 1: Acquisition Details - Zhonghong Medical's wholly-owned subsidiary, Zhonghong International, and its controlling subsidiary, Guilin Hengbao, signed an agreement to acquire 75% of SEA3 for a total of 6.97 yuan [1][3]. - SEA3, established in September 2016, specializes in the production and sale of medical gloves and has certifications for compliance with EU and US market standards [2][4]. - As of the end of last year, SEA3 had total assets of 141 million yuan and a net asset value of -1.2 million yuan, indicating financial distress [2][4]. Group 2: Financial Assessment - The assessed value of SEA3's total equity was determined to be 802,300 yuan, reflecting a significant increase of 271,240 yuan (142%) over its book value [2][3]. - The transaction price was based on this assessed value, with Zhonghong International acquiring 52.5% and Hengbao acquiring 22.5% of the equity [3]. Group 3: Strategic Intent - The primary goal of the acquisition is to secure a production base in Southeast Asia, which is crucial for adapting to changes in the international trade environment [5][6]. - Zhonghong Medical aims to leverage SEA3's existing certifications and production capabilities to enhance its market position and overall competitiveness in the medical supplies industry [5][6]. Group 4: Future Outlook - Despite SEA3's current operational challenges, Zhonghong Medical remains optimistic about the future growth of the medical glove market, anticipating increased demand driven by global health trends [5][6]. - The company plans to implement effective post-investment management and operational synergies to help SEA3 return to profitability [5][6].